Clinical EffectsOne study looked at using Perjeta in combination with docetaxel (Taxotere®) and trastuzumab (Herceptin®) as a biological therapy for the treatment of metastatic breast cancers (breast cancer that has spread to other parts of the body) that were HER2-positive. When all three medications were combined in these cases, "progression-free survival" (the time without death or worsening of the cancer) was increased, compared to taking just docetaxel and trastuzumab (without Perjeta).
When and How to Receive ItSome general considerations to keep in mind during treatment with Perjeta include the following:
- It is given intravenously (by IV) every three weeks.
- Your first Perjeta infusion will last 60 minutes, and subsequent infusions may be shorter (usually 30 to 60 minutes).
- Most people receive their infusion at their healthcare provider's office, a hospital, or at an "infusion center."
- For the medication to work properly, it must be used as prescribed. Perjeta will not work as well if you stop using it before your healthcare provider recommends.
Dosing InformationThere is only one standard dose of Perjeta, regardless of your age or weight. As is always the case, do not adjust your dose unless your healthcare provider specifically tells you to do so.
(Click Perjeta Dosage for more information.)
Side Effects of PerjetaJust like any medicine, Perjeta may cause side effects. However, not everyone who receives the drug will experience problems. In fact, most people tolerate it quite well.
If reactions do occur, in most cases, they are minor and either require no treatment or are treated easily by you or your healthcare provider. Serious side effects are less common.
Common side effects of the Perjeta/trastuzumab/docetaxel combination include but are not limited to:
- Hair loss
(Click Perjeta Side Effects to learn more, including potentially serious side effects you should report immediately to your healthcare provider.)